Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2025 08:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Submits Response to the FDA’s CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting

MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration...
May 28, 2025 08:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

MONTREAL AND CHARLOTTE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief...
May 14, 2025 07:04 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

Resolution of CRL Manufacturing issues in progress - Type A meeting requested No clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE...
March 28, 2025 07:00 ET | Source: Milestone Pharmaceuticals Inc.

FDA Issues Complete Response Letter for Etripamil for PSVT

CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28,...
March 20, 2025 08:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology

MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...
March 13, 2025 07:08 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update

FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for...
March 04, 2025 08:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards,...
February 27, 2025 08:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

MONTREAL and CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45th...
February 19, 2025 08:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil

MONTREAL and CHARLOTTE, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...
February 11, 2025 08:00 ET | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

MONTREAL and CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...